LIXTE Biotechnology Advances LB-100 Pipeline and Expands Proton Therapy Operations
LIXTE Biotechnology reports first-quarter progress with its lead cancer drug LB-100 moving into expanded ovarian cancer trials and growth at its Liora Technologies subsidiary, signaling strategic expansion in oncology.
